- Home
- CXDO vs SLS Comparison
CXDO vs SLS Comparison
Compare CXDO & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXDO
- SLS
- Stock Information
- Founded
- CXDO 1995
- SLS 2012
- Country
- CXDO United States
- SLS United States
- Employees
- CXDO N/A
- SLS N/A
- Industry
- CXDO Telecommunications Equipment
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- CXDO Telecommunications
- SLS Health Care
- Exchange
- CXDO Nasdaq
- SLS Nasdaq
- Market Cap
- CXDO 198.8M
- SLS 185.3M
- IPO Year
- CXDO 1998
- SLS N/A
- Fundamental
- Price
- CXDO $6.64
- SLS $1.69
- Analyst Decision
- CXDO Strong Buy
- SLS Strong Buy
- Analyst Count
- CXDO 4
- SLS 1
- Target Price
- CXDO $8.75
- SLS $7.00
- AVG Volume (30 Days)
- CXDO 117.1K
- SLS 2.0M
- Earning Date
- CXDO 11-05-2025
- SLS 11-12-2025
- Dividend Yield
- CXDO N/A
- SLS N/A
- EPS Growth
- CXDO 13.31
- SLS N/A
- EPS
- CXDO 0.11
- SLS N/A
- Revenue
- CXDO $64,476,000.00
- SLS N/A
- Revenue This Year
- CXDO $13.46
- SLS N/A
- Revenue Next Year
- CXDO $11.81
- SLS N/A
- P/E Ratio
- CXDO $60.99
- SLS N/A
- Revenue Growth
- CXDO 13.10
- SLS N/A
- 52 Week Low
- CXDO $3.75
- SLS $0.77
- 52 Week High
- CXDO $7.34
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- CXDO 56.55
- SLS 42.73
- Support Level
- CXDO $6.37
- SLS $1.65
- Resistance Level
- CXDO $6.98
- SLS $2.01
- Average True Range (ATR)
- CXDO 0.31
- SLS 0.11
- MACD
- CXDO 0.02
- SLS -0.02
- Stochastic Oscillator
- CXDO 57.50
- SLS 11.11
About CXDO Crexendo Inc.
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.